Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer

This study is a single center, open-label, non-comparative, phase I/II clinical trial to assess the maximum tolerated dose (MTD), safety and efficacy of BEY1107 in monotherapy and in combination with gemcitabine in patient With locally advanced or metastatic pancreatic cancer.

Trial Details

NCT ID

NCT03579836

Phase

PHASE1 / PHASE2

Sponsor

BeyondBio Inc.

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

BEY1107
Gemcitabine

Locations (sample)

Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

Histologically or Cytologically confirmed with pancreatic ductal adenocarcinoma or undifferentiated carcinoma of the pancreas
At lease one measurable lesion according to RECIST v.1.1
Eastern Cooperative Oncology Group (ECOG) 0,1 or 2
Over 12 weeks of Life expectancy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →